[ 123I]-Meta-Iodobenzylguanidine Scintigraphy in Sarcoidosis: Exploring Cardiac Autonomic Dysfunction in Patients with Unexplained Cardiac Symptoms.

Publication date

2025-09-11

Authors

Raasing, Lisette R M
Drent, Marjolein
Keijsers, Ruth G M
van den Hoven, Andor
Post, M. C.
Grutters, JCISNI 0000000396090380
Veltkamp, Marcel

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Background/Objectives: Sarcoidosis is a systemic inflammatory disease that can cause cardiac autonomic dysfunction (SCAD), often underrecognized despite its clinical importance. While [ 18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([ 18F]FDG PET/CT) and cardiac magnetic resonance imaging (CMR) assess cardiac involvement, [ 123I]-meta-iodinebenzylguanidine ([ 123I]MIBG) scintigraphy evaluates cardiac sympathetic innervation, offering complementary insights to potentially improve SCAD detection and management. This retrospective study explores the role of [ 123I] MIBG scintigraphy in detecting SCAD among patients with unexplained cardiac symptoms. It focuses on its potential to provide complementary diagnostic information in patients where established imaging techniques, such as [ 18F]FDG PET/CT and CMR, fail to detect cardiac sarcoidosis. Methods: Sarcoidosis patients referred to the St. Antonius Hospital (2017-2024) who underwent [ 123I]MIBG scintigraphy were included. Collected data encompassed demographics, SCAD symptoms, cardiac imaging findings, and carvedilol treatment outcomes. [ 123I] MIBG abnormalities were defined as a heart-to-mediastinal ratio ≤1.6 or a washout rate ≥20%. Results: Among the final cohort of 40 sarcoidosis patients with unexplained cardiac symptoms and normal [ 18F]FDG PET/CT and CMR findings, 19 patients (48%) showed abnormal [ 123I] MIBG scintigraphy results suggestive of SCAD. No significant differences were observed in clinical characteristics between patients with normal and abnormal [ 123I]MIBG findings. Of the 16 patients treated with carvedilol, 88% reported symptom improvement, although 50% experienced side effects. Conclusions: [ 123I]MIBG scintigraphy revealed abnormalities in a substantial number of sarcoidosis patients with unexplained cardiac symptoms despite normal [ 18F]FDG PET/CT and CMR. These findings indicate a potential role for [ 123I]MIBG in detecting SCAD, but prospective studies are needed to confirm their clinical significance.

Keywords

MIBG, autonomic dysfunction, cardiac disease, sarcoidosis, small fiber neuropathy, Internal Medicine, Clinical Biochemistry

Citation

Raasing, L R M, Drent, M, Keijsers, R G M, van den Hoven, A F, Post, M C, Grutters, J C & Veltkamp, M 2025, '[ 123I]-Meta-Iodobenzylguanidine Scintigraphy in Sarcoidosis : Exploring Cardiac Autonomic Dysfunction in Patients with Unexplained Cardiac Symptoms.', Diagnostics, vol. 15, no. 18, 2306. https://doi.org/10.3390/diagnostics15182306